We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Last year Peter Sarnow, PhD, professor of microbiology and immunology at the Stanford University School of Medicine, identified a previously unknown mechanism that the hepatitis C virus uses to replicate, yielding a promising new approach to combating the disease-causing virus.
Shanghai Worldbest Pharmaceutical Co, a subsidiary of state-owned China Worldbest Group, admitted yesterday it inflated profits totaling 65.11 million yuan (US$8.1 million) from 2001 to 2004.
A Laval firm developing drugs to fight diabetes and obesity entered the industry in a novel way, and its strategy is paying off. Unlike most pharmaceutical start-ups, Innodia Inc. wasn't rolled out of a university laboratory or split off a larger drug company.
A recent report issued by the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) has shown that approximately 60 percent of all medicines available in the country are not registered by the agency.
Canadian pharmaceutical company Merck Frosst Canada and Génome Québec have signed a research agreement whereby each will invest $5.28 million over three years in the discovery and development of treatments for life-threatening fungal infections.
Swiss drugmaker Roche has reported that the first-ever Phase III study investigating Xeloda (capecitabine) as a first-line treatment in advanced stomach cancer has successfully met its primary endpoint.
San Francisco-based life sciences company Burrill has formed a partnership with Beijing Pharmaceutical Group (BPGC), one of the largest pharmaceutical and medical device companies in China, to develop and manufacture new pharmaceutical products.
Forest Laboratories Inc. and closely held, Barcelona-based pharmaceutical company Almirall agreed to develop, market and distribute the Spanish company's chronic obstructive pulmonary disease treatment, LAS34273, in the U.S.
Neuromed Pharmaceuticals, a biopharmaceutical company developing next-generation chronic pain drugs, today announced the appointment of Dr. Stephen Arneric to its executive team.